Article info
PDFImage of the moment
Capecitabine leukoencephalopathy
- Correspondence to Dr Zeid Yasiry, Department of Neurology, Sheffield Teaching Hospital NHS Trust, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; zeid.yasiry{at}nhs.net
Citation
Capecitabine leukoencephalopathy
Publication history
- Accepted December 7, 2018
- First published January 5, 2019.
Online issue publication
May 21, 2019
Article Versions
- Previous version (5 January 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients
- What to see when you are looking at confusion: a review of the neuroimaging of acute encephalopathy
- Cortical abnormalities on MRI: what a neurologist should know
- Persistent lesion hyperintensity on brain diffusion-weighted MRI is an early sign of intravascular lymphoma
- Hereditary diffuse leukoencephalopathy with neuroaxonal spheroids: novel imaging findings
- A review of structural magnetic resonance neuroimaging
- Evaluation of mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) by diffusion-weighted and diffusion tensor imaging
- Alternating hemiparesis and orolingual apraxia as manifestations of methotrexate neurotoxicity in a paediatric case of acute lymphoblastic leukaemia
- Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES)
- Neuroimaging findings in newborns with congenital heart disease prior to surgery: an observational study